2024
Perceptions Around Vocal Health Among Group Fitness Instructors and Pilot Use of Group Fitness Instructor–Specific Voice Handicap Questionnaire
Dacey S, Koppel S, Keltz A, Livecchi D, Kohli N, Lerner M. Perceptions Around Vocal Health Among Group Fitness Instructors and Pilot Use of Group Fitness Instructor–Specific Voice Handicap Questionnaire. Perspectives Of The ASHA Special Interest Groups 2024, 9: 512-517. DOI: 10.1044/2024_persp-23-00259.Peer-Reviewed Original ResearchGroup fitness instructorsHandicap QuestionnaireHealth careFitness instructorsNon-VP groupPrimary care providersVoice problemsHealth maintenance behaviorsSinging Voice Handicap Index-10Care providersHealth challengesVocal healthVoice Handicap Index-10Increased riskDemographic dataFitness industryCareStatistically significant differencePilot useVP groupQuestionnaireVoice demandsOccupational voice demandScoresSurvey
2022
Long-term laryngological sequelae and patient-reported outcomes after COVID-19 infection
Shah H, Bourdillon A, Panth N, Ihnat J, Kohli N. Long-term laryngological sequelae and patient-reported outcomes after COVID-19 infection. American Journal Of Otolaryngology 2022, 44: 103780. PMID: 36592551, PMCID: PMC9798664, DOI: 10.1016/j.amjoto.2022.103780.Peer-Reviewed Original ResearchConceptsCOVID-19 infectionReflux Symptom IndexLaryngotracheal stenosisCough Severity IndexLaryngeal dysfunctionDyspnea indexSymptom improvementCOVID clinicProcedural interventionQOL indexVoice therapyEating Assessment Tool-10Assessment Tool-10Fellowship-trained laryngologistsIntubation/tracheostomyVoice Handicap Index-10Non-intubated patientsPatient-reported outcomesCOVID-19COVID-19 diagnosisPatient demographicsLaryngeal hypersensitivitySymptom IndexMean durationInclusion criteriaIncobotulinimtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: A prospective, open-label clinical trial
Kohli N, Lerner M, Rashty J, Kirke D, Stewart T, Blitzer A. IncobotulinimtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: A prospective, open-label clinical trial. American Journal Of Otolaryngology 2022, 43: 103613. PMID: 36055061, DOI: 10.1016/j.amjoto.2022.103613.Peer-Reviewed Original ResearchConceptsAdductor spasmodic dysphoniaSpasmodic dysphoniaOpen-label clinical trialProspective open-label trialAdductor laryngeal dystoniaOpen-label trialFirst-line treatmentVoice Handicap Index-10Side effect profileTransient side effectsNormal functionVHI-10 scoresIncobotulinumtoxinA injectionsEffect profileLine treatmentSystemic diseaseTA muscleBotulinum toxinClinical trialsLaryngeal dystoniaNursing womenThyroarytenoid muscleInjection sessionsExclusion criteriaSide effects
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply